Navigation Links
Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009
Date:10/29/2008

- Second Fiscal Quarter Net Sales of $3.9 Million; 29% Increase

Year-Over-Year -

- Second Fiscal Quarter U.S. Sales of $2.2 Million; 83% Increase

Year-Over-Year - - Multicenter Clinical Study Launched to Expand Reimbursement, Support

Marketing -

- Conference Call to be Held Today at 3:30 pm Central Time -

MINNEAPOLIS, Oct. 29 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the second quarter of fiscal 2009 ended September 30, 2008. Net sales for the second quarter of fiscal 2009 were $3.9 million, up 29% from $3.0 million in the second quarter of fiscal 2008. U.S. sales were $2.2 million, an increase of 83% from $1.2 million in the second quarter of fiscal 2008.

"During our second fiscal quarter, our team continued to execute our strategies and we generated solid growth," said David Kaysen, President and CEO. "In the U.S., support for the Urgent PC(R) system is continuing to build after the release of the initial results of the OrBIT study in May which demonstrated Urgent PC's efficacy to be comparable to the number-one prescribed pharmaceutical for overactive bladder. In addition, we continued to make progress in building sales of Macroplastique(R), which we introduced in the U.S. market in mid-2007," added Mr. Kaysen.

The Urgent PC system is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary frequency, urinary urgency and urge incontinence -- symptoms often associated with overactive bladder. The system is an office-based, nonsurgical, percutaneous tibial nerve stimulation (PTNS) device that treats these symptoms. Macroplastique is an injectable urethral bulking agent for the treatment of
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Uroplasty to Present at the Noble Financial Fourth Annual Equity Conference
2. Uroplasty to Host First Quarter Conference Call on July 31
3. Uroplasty Joins the Russell Microcap Index
4. Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008
5. Uroplasty to Host Fourth Quarter and Year End Conference Call on June 3
6. Uroplasty to Highlight Urgent PC System at American Urological Association 2008 Annual Meeting
7. Uroplasty Plans to Double Sales Force During Fiscal 2009
8. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
9. Uroplasty to Present at ROTH Capital Partners 20th Annual OC Growth Stock Conference
10. Uroplasty Expands Marketing Program for Urology Practices
11. Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Red Reflex Vision Exam Should Be Given to All Newborns Report Recommends 60862 1Red Reflex Vision Exam Should Be Given to All Newborns Report Recommends 60862 2Red Reflex Vision Exam Should Be Given to All Newborns Report Recommends 60862 3Journal of Public Health Management 26amp 3B Practice Calls for Growth in Public Health Workforce 60859 1Journal of Public Health Management 26amp 3B Practice Calls for Growth in Public Health Workforce 60859 2Journal of Public Health Management 26amp 3B Practice Calls for Growth in Public Health Workforce 60859 3Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 60856 1Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 60856 2Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 60856 3